The most structurally radical aspect of RiboX Therapeutics’ FDA IND clearance for RXIM002 is not the circular RNA format itself, but what the agency agreed to on the back of it: an accelerated dose-titration scheme and a subcutaneous formulation, both granted because Chinese investigator-initiated trial data were accepted as sufficiently robust to shape the U.S. trial design from day one. That is an unusual concession, and it signals that the FDA found the existing human dataset credible enough to compress the standard Phase 1 safety ramp rather than demand it be rebuilt on American soil.
RXIM002 encodes an anti-CD19 chimeric antigen receptor delivered via targeted lipid nanoparticles loaded with circular RNA. The circular RNA format confers greater stability than linear mRNA and enables durable CAR expression without integrating into the genome. Critically, T cells are reprogrammed inside the patient’s body, which eliminates the weeks-long, facility-intensive ex vivo manufacturing process that has constrained conventional CAR-T access. The POPULUS-1 Phase 1 trial will open in relapsed or refractory immune thrombocytopenia, a condition in which pathogenic autoantibodies driven by aberrant B-cell activation destroy platelets. ITP now has approved oral options, including rilzabrutinib, cleared by the FDA in September 2025 for adults with persistent or chronic ITP who did not respond adequately to immunoglobulins, anti-D therapy, or corticosteroids. The existence of that approval makes RXIM002’s endpoint design a genuine clinical question: the trial will need to show not just platelet recovery, but depth and durability of B-cell depletion consistent with immune reset, a bar rilzabrutinib does not claim to clear.
The subcutaneous formulation is strategically significant beyond convenience. CAR-T therapies have historically required inpatient administration tied to lymphodepletion regimens and cytokine release monitoring. If in vivo generation of CAR-T cells via a subcutaneous injection proves safe in the outpatient setting, it rewrites the logistics of the entire category. The IIT follow-up data, with some patients now beyond six months of observation, will be the substrate the POPULUS-1 investigators use to calibrate dose levels and watch for delayed immune-related signals that shorter follow-up cannot capture. RiboX submitted the complete dataset to the FDA rather than selected summaries, a transparency choice that appears to have directly influenced the agency’s willingness to accept the accelerated scheme.
The one number that will define this program’s near-term credibility is the proportion of POPULUS-1 participants who achieve a platelet count at or above 50 x 10⁹/L without rescue therapy at 90 days post-infusion, the kind of durable, treatment-free response that distinguishes immune reset from transient suppression. If that figure emerges from early cohorts with a clean safety profile, the in vivo circRNA CAR-T platform moves from an elegant concept to a replicable clinical result.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
